Clinical Research Directory
Browse clinical research sites, groups, and studies.
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
Sponsor: Javier Toledo
Summary
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
6000
Start Date
2025-12-20
Completion Date
2028-08-01
Last Updated
2026-01-02
Healthy Volunteers
Yes
Conditions
Interventions
DiNanoQ: A multi-cancer early detection (MCED) blood test
Procedure: Participants will undergo a single blood draw at baseline. Sample Analysis: Platelet Isolation: Platelets will be extracted from the collected blood samples. RNA Analysis: RNA from the isolated platelets will be extracted and analyzed using AI-based transcriptomic profiling to identify biomarkers associated with cancer.
DiNanoTrack: Therapeutic Response Monitoring Blood Test
Procedures: Blood Sample Collection: Participants will have blood samples drawn at three time points: Baseline: Before therapy initiation. 6 Weeks Post-Therapy Initiation: To monitor early treatment response. 6 Months Post-Therapy Initiation: To assess longer-term therapeutic outcomes. Sample Analysis: Platelet and Immune Cell Isolation: Platelets: Extracted from each blood sample to continue monitoring RNA profiles. Immune Cells: Separated from the blood samples to analyse immune response to therapy. RNA Analysis: Platelet RNA: Analysed to observe changes in transcriptomic profiles over time using AI-based tools. Immune Cell RNA: Examined to assess transcriptomic changes associated with therapeutic responses. Data Correlation: Therapeutic Response Assessment: RNA profiles from platelets and immune cells will be correlated with clinical outcomes to identify biomarkers predictive of treatment efficacy, progression-free survival, relapse, and drug resistance.
Locations (4)
Various Cancer Centres
Rosario, Argentina
NSIA- Lagos University Teaching Hospital Cancer Centre
Lagos, Nigeria
Babraham Research Institute
Cambridge, United Kingdom
Dysplasia Diagnostics Limited
London, United Kingdom